Asset Details
Do you wish to reserve the book?
Real-world testing of serum lactate dehydrogenase among patients with metastatic colorectal cancer in the United States
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Real-world testing of serum lactate dehydrogenase among patients with metastatic colorectal cancer in the United States
Do you wish to request the book?
Real-world testing of serum lactate dehydrogenase among patients with metastatic colorectal cancer in the United States
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Real-world testing of serum lactate dehydrogenase among patients with metastatic colorectal cancer in the United States
2025
Overview
Abstract
Background
Serum lactate dehydrogenase (LDH) is a potential prognostic biomarker of outcomes in patients with metastatic colorectal cancer (mCRC). This retrospective, observational study assessed real-world LDH testing patterns and LDH as a prognostic factor for overall survival (OS) in US patients receiving chemotherapy for mCRC.
Methods
Patients with mCRC who initiated first-line chemotherapy between January 1, 2016, and November 30, 2022, were selected from a nationwide de-identified Electronic Health Record-derived database. LDH value was categorized based on laboratory reference ranges. The prognostic relationship between pretreatment LDH value and OS was assessed using Kaplan–Meier and multivariate Cox proportional-hazards models.
Results
Of 15 329 adult patients (median age 64 years), 3379 (22%) had LDH testing at or postindex; 21% had abnormal baseline values, while 40% had normal values. Patients with abnormal LDH levels were more likely to be female (47% abnormal LDH vs 41% normal LDH), ≥ 65 years of age (52% vs 49%), Black or African American (12% vs 7%), or reside in the Northeast (30% vs 21%). The median OS (95% CI) in patients with normal baseline LDH was 29.9 (28.3-31.7) vs 16.8 (14.8-18.2) months for those with abnormal LDH. In a multivariate Cox proportional-hazards model, patients with abnormal baseline LDH had higher risk of death (HR 1.91, P < .0001) after adjustment for demographic/clinical characteristics.
Conclusions
Abnormal baseline LDH levels were associated with shorter OS; however, only one-fifth of patients receiving chemotherapy underwent LDH testing. Efforts to increase LDH testing could be valuable in helping guide treatment decisions.
Publisher
Oxford University Press
